Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

Clinical Pharmacology and Therapeutics
M T BorinW W Freimuth

Abstract

To study the effect of rifampin (INN, rifampicin), a potent inducer of cytochrome P450, on the steady-state pharmacokinetics of delavirdine. Twelve patients who were positive for human immunodeficiency virus, with CD4 counts ranging from 110 to 483/mm3, were randomized to two groups and studied in parallel. Both the control group (n = 5) and the rifampin group (n = 7) received 400 mg delavirdine mesylate every 8 hours for 30 days; subjects in the rifampin group took a 600 mg once-daily dose of rifampin on days 16 through 30. Harvested plasma from serial blood samples collected after dosing on days 15, 16, and 30 was assayed for delavirdine and its N-desalkyl metabolite concentrations with a reversed-phase HPLC method. Blood samples obtained on days 16 and 30 were also assayed for rifampin by HPLC. Delavirdine mesylate alone and in combination with rifampin was well tolerated. On day 30, statistically significant differences between groups were observed for all delavirdine pharmacokinetic parameters (p < 0.049). In the rifampin group, delavirdine oral clearance increased by about 27-fold (p = 0.022), resulting in virtually negligible (< 0.09 mumol/L) steady-state through drug concentrations in all patients after 2 weeks of concu...Continue Reading

References

Mar 1, 1978·Clinical Pharmacokinetics·G Acocella
Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Apr 1, 1992·Archives of Internal Medicine·S M BorcherdingT H Self
Jan 1, 1992·Clinical Pharmacokinetics·K Venkatesan
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D L RomeroL Resnick
Jul 1, 1991·European Journal of Drug Metabolism and Pharmacokinetics·S K GargP L Sharma
Jan 1, 1990·Pharmacology & Therapeutics·A B Okey
Jan 1, 1988·European Journal of Clinical Pharmacology·E PeruccaE E Ohnhaus
May 1, 1988·The Journal of Antimicrobial Chemotherapy·N DobleE E Keal
Jan 1, 1981·Clinical Pharmacokinetics·B K Park, A M Breckenridge
Aug 1, 1984·Archives of Internal Medicine·A M Baciewicz, T H Self
May 1, 1993·Antimicrobial Agents and Chemotherapy·T J DuewekeL Resnick
Feb 9, 1996·Journal of Chromatography. B, Biomedical Applications·Y Y LauB J Carel

❮ Previous
Next ❯

Citations

Jun 22, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G Gerber
Jul 28, 2010·Antimicrobial Agents and Chemotherapy·Marc WeinerAndrew Vernon
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·Mark J SheltonGene D Morse
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·J A H DrosteD M Burger
Jan 13, 2010·Clinical Microbiology Reviews·Graeme N Forrest, Kimberly Tamura
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Aug 19, 2007·Expert Opinion on Drug Metabolism & Toxicology·Andrew Walubo
Nov 26, 2015·Expert Opinion on Drug Metabolism & Toxicology·Amina I ShehuXiaochao Ma
Jan 10, 2012·Scandinavian Journal of Infectious Diseases·Abida ShaheenZia-Ur-Rehman Farooqi
Jan 26, 2006·British Journal of Clinical Pharmacology·Kwee Poo YeoStephen D Wise
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Qing MaGene D Morse
Nov 15, 2003·Journal of Clinical Pharmacology·Mark Alastair BoydIndravadan H Patel
Jun 13, 2015·Clinical Drug Investigation·Jeanne MendellDolly A Parasramupria
Jul 4, 2001·Clinical Pharmacokinetics·W J BurmanC Peloquin
May 1, 2001·Clinical Pharmacokinetics·J Q TranB M Kerr
Dec 12, 2001·Clinical Pharmacokinetics·P F SmithG D Morse
May 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·J Gill, J Feinberg
Mar 13, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·W W Yew
Feb 27, 2003·Clinical Pharmacokinetics·Monique M R de MaatJos H Beijnen
Jul 29, 2003·Clinical Pharmacokinetics·Mikko NiemiKari T Kivistö
Mar 29, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yang XuGary L Skiles
Mar 5, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Cho-Ming LoiDeepak Dalvie
Nov 18, 2003·British Journal of Clinical Pharmacology·Lynn PurkinsEdward R Love
Jul 17, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J J FerryD H Batts
Apr 10, 1999·AIDS·A L PozniakL P Ormerod
Jul 17, 1998·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Y NishibeK Ohno
Mar 30, 2000·Infectious Disease Clinics of North America·P CahnG Prada-Trujillo
Dec 7, 2007·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·P AmarilesM J Faus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.